Skip to content
vigabatrin.org

Tuberous sclerosis complex (TSC)

On this page

Short answer: tuberous sclerosis complex (TSC) is a genetic condition that makes noncancerous (benign) growths form in many parts of the body, including the brain, kidneys, heart, skin, lungs and eyes. It is caused by a change in the TSC1 or TSC2 gene and affects about 1 in 6,000 to 10,000 people.1 Seizures are very common in TSC: about 85% of people with TSC have them, and most start in the first year of life.2

TSC varies a great deal from person to person. Some people have normal intelligence and no seizures; others have intellectual disability or seizures that are hard to control.3 This page explains what tuberous sclerosis is, how it is passed on and diagnosed, the signs to look for in babies and children, and how it is treated. Your child's TSC team is the best guide to your child's own care.

What is tuberous sclerosis complex?

The TSC1 and TSC2 genes carry the instructions for two proteins, hamartin and tuberin. Together they keep cell growth, cell division and cell size in check, so they act as tumor suppressors. A person with TSC is usually born with one altered copy of one of these genes in every cell. A growth forms when a second change hits the other copy in a group of cells during life. Those cells then grow and divide without the usual brakes.1

The missing brake works through a growth signal inside cells called mTOR. In TSC, mTOR is switched on all the time, and that drives the growth of benign tumors in several organs. This is why medicines that block mTOR, such as everolimus, are used in TSC.4

Cortical tubers, areas of abnormal development in the outer layer of the brain, are found in about 90% of people with TSC.5 In US medical coding, tuberous sclerosis is ICD-10-CM code Q85.1.6

Is tuberous sclerosis inherited?

TSC is autosomal dominant: one altered copy of the gene is enough to cause it. In about one third of cases, a child inherits the altered gene from a parent who has TSC. The other two thirds are born with a new gene change and have no family history of TSC.1 A parent with TSC has a 50% chance of passing it on to each child.3

A few people carry the gene change in only some of their cells (mosaicism).1 Genetic counseling is recommended for couples with a personal or family history of TSC who want to have children.3

How is tuberous sclerosis diagnosed?

There are two routes to a diagnosis. The first is genetic: finding a clearly harmful change in TSC1 or TSC2 is enough on its own. But 10% to 25% of people with TSC have no change found by standard genetic testing, so a normal result does not rule TSC out.5

The second route uses clinical features. The international consensus lists major and minor features:5

  • Major features: 3 or more pale skin patches at least 5 mm wide (hypomelanotic macules); 3 or more angiofibromas or a fibrous plaque on the head; 2 or more fibromas around the nails (ungual fibromas); a shagreen patch; several growths on the retina (retinal hamartomas); tubers or other areas of abnormal brain development; subependymal nodules; SEGA; cardiac rhabdomyoma; LAM; and 2 or more angiomyolipomas.
  • Minor features: "confetti" skin spots, pits in the tooth enamel, 2 or more fibromas inside the mouth (intraoral fibromas), a pale patch on the retina, several kidney cysts, and benign growths (hamartomas) in other organs.

A definite diagnosis needs 2 major features, or 1 major feature plus 2 or more minor ones. One major feature, or 2 or more minor ones, makes it a possible diagnosis.5 The 2021 update kept this framework with two changes: "multiple cortical tubers and/or radial migration lines" replaced the broader term for abnormal brain development, and sclerotic bone lesions came back as a minor feature.7

Tests may include an MRI or CT scan of the head, an echocardiogram (heart ultrasound), a kidney ultrasound, a chest CT, a skin check under ultraviolet light, and DNA testing.3

What are the symptoms of tuberous sclerosis by age?

Different signs tend to appear at different ages, which is why some show up only years after diagnosis.

Before birth and in newborns

  • Heart tumors (cardiac rhabdomyomas). These are often the first sign of TSC and are frequently seen on ultrasound before birth. A rhabdomyoma found before birth carries a 75% to 80% chance that the baby has TSC. They usually need no surgery and often shrink after birth.3,5 If a baby is found to have one, a genetics specialist should be involved.3
  • Brain findings. Subependymal nodules (small growths along the walls of the fluid spaces in the brain) are seen in 80% of people with TSC.5

Babies and toddlers

  • Pale skin patches. Hypomelanotic macules are found in about 90% of people with TSC. They usually appear at birth or in infancy and can be the first sign.5 Their shape is sometimes compared to an ash leaf, which is why they are called ash leaf spots.3
  • Seizures. In one large registry, the average age at diagnosis of infantile spasms was 0.4 years, about 5 months.8

Children

  • Facial angiofibromas. Red patches on the face that contain many tiny blood vessels are found in about 75% of people with TSC. They usually start between ages 2 and 5.5
  • Shagreen patch. A raised patch of skin with a bumpy, orange-peel surface, most often on the lower back.5
  • SEGA. A subependymal giant cell astrocytoma (SEGA) is a brain tumor that develops in 5% to 15% of people with TSC, mostly in childhood or the teenage years. It can block the flow of brain fluid (hydrocephalus).5
  • TAND. TSC-associated neuropsychiatric disorders include hyperactivity, aggression, intellectual disability, autism spectrum disorder and other psychiatric conditions. ADHD is also seen.1 The 2021 consensus put more emphasis on checking for and managing TAND.7

Teenagers and adults

  • Nail fibromas. Growths around or under the nails are found in about 20% of people with TSC overall, but in up to 80% of older adults, because they usually appear from the teenage years on.5
  • Kidney angiomyolipomas. Kidney tumors are common in TSC and can cause serious problems with kidney function.1 As they grow, they can bleed or harm the kidneys.9 Regular kidney ultrasounds are important.3
  • LAM. Lymphangioleiomyomatosis is a lung disease that mainly affects women with TSC. It can cause coughing, shortness of breath, chest pain and lung collapse.1 Lung changes consistent with LAM are seen in 30% to 40% of women with TSC, and symptoms usually start in the 20s or 30s.5

How common is epilepsy in tuberous sclerosis?

Most people with TSC develop epilepsy, and it usually starts early:

  • In a US clinic study of 291 people with TSC, 85.2% had had seizures, 37.8% had had infantile spasms, and 63.2% had their first seizure in the first year of life. More than half went on to have more than one seizure type.2
  • In the international TOSCA registry of 2,216 people, 83.6% had epilepsy, 38.9% had infantile spasms and 67.5% had focal seizures. 79.3% were diagnosed before age 2. Spasms were about twice as common with a TSC2 change as with a TSC1 change (47.3% vs 23%).8

Seizures in TSC are often hard to treat: in the US study, 62.5% of people with epilepsy developed drug-resistant epilepsy, though a third reached remission. Infantile spasms raised the risk of hard-to-treat epilepsy, and an earlier start and harder-to-control seizures were linked to poorer learning and development.2 In TOSCA, seizure control was linked to lower rates of intellectual disability.8

Focal seizures can start at any age, sometimes before infantile spasms do.8

Why EEG checks matter in a baby with TSC

An EEG records the brain's electrical activity; with spasms it can show a pattern called hypsarrhythmia, one sign of West syndrome. The 2021 international consensus gave more weight to early EEG screening for seizure-type (epileptiform) activity in TSC.7 In the PREVeNT trial, the first abnormal EEG was the signal to start treatment, before any seizure had been seen.10

Two trials tested giving vigabatrin before seizures start. In the EPISTOP trial, early treatment delayed the first seizure and lowered the risk of drug-resistant epilepsy.11 In PREVeNT, early treatment did not improve development at 24 months or reduce focal seizures, although infantile spasms were less common.10 Preventive treatment is still debated.

Treating seizures in TSC: why vigabatrin comes first

For infantile spasms caused by TSC, vigabatrin is the first-line medicine.3 In pooled early reports, spasms stopped completely in 95% of babies with TSC, against 54% of babies with other causes.12 A review of 28 treatment guidelines from around the world found that every one recommended vigabatrin first for spasms caused by TSC.13

Spasms stopped completely with vigabatrin, by cause12
  • Tuberous sclerosis complex
  • Other causes
Tuberous sclerosis complex (73 of 77)
95%
Other causes (170 of 313)
54%

Pooled published reports, 1999 review.

Show as a table
GroupMeasureValue
Spasms stopped completely with vigabatrin, by causeTuberous sclerosis complex (73 of 77)95%
Spasms stopped completely with vigabatrin, by causeOther causes (170 of 313)54%

Vigabatrin carries a boxed warning for permanent vision loss, so eye checks are needed at the start (no later than 4 weeks in), at least every 3 months on treatment, and about 3 to 6 months after stopping.14

Which form of vigabatrin for a baby

The first days of treatment matter: in a large US study, the median time to response on vigabatrin was 3 days.15 That makes it worth getting the dose right from the very first day. Vigabatrin powder has to be mixed with water before every dose. Every vigabatrin form is the same medicine.14 The ready-to-use liquid (Vigafyde) is labeled, like other vigabatrin forms, for infantile spasms of any cause from 1 month to 2 years. It needs no mixing; in one small study funded by its maker, doses prepared from it were more accurate than doses mixed from powder.14,16 Practical tips are in our guide on how to give liquid medicine to a baby.

What is the treatment for tuberous sclerosis?

There is no cure for TSC, so care is built around the problems each person has.3

  • Everolimus (an mTOR blocker). It is approved for SEGA brain tumors that need treatment but cannot be fully removed, in people aged 1 year and older. One form, a tablet for oral suspension, is approved as an add-on for TSC-related focal (partial-onset) seizures from age 2. It is also approved for adults with kidney angiomyolipomas that do not need surgery right away.17
  • The EXIST trials. In EXIST-1, SEGA volume halved in 35% of patients on everolimus and in none on placebo.4 In EXIST-2, angiomyolipoma volume halved in 42% of adults on everolimus and in none on placebo.9 In EXIST-3, seizures fell by half or more in 40.0% of patients on the higher everolimus exposure, 28.2% on the lower exposure and 15.1% on placebo. Mouth sores were common, and all three trials were funded by the drug's maker.4,9,18
  • Surgery and other procedures. Some children with seizures need surgery. Kidney tumors may be treated with surgery or by reducing their blood supply with special x-ray techniques, and everolimus may be used for kidney tumors that do not need surgery right away. Facial angiofibromas can be treated with laser, although they tend to come back.3
  • Heart tumors. Cardiac rhabdomyomas usually need no surgery and often shrink after birth.3,5
  • Learning and behavior. Depending on the degree of intellectual disability, a child may need special education.3 The 2021 consensus called for closer checks and management of TAND.7

What is the outlook for a child with tuberous sclerosis?

Children with mild TSC most often do well. Children with severe intellectual disability or seizures that cannot be controlled often need help throughout life. The tumors are usually benign, but some, such as kidney or brain tumors, can become cancerous.3 Children whose seizures are controlled tend to have better learning and development.2,8

Short answers to common questions about vigabatrin are in the vigabatrin FAQ.

Support for families

These groups support families living with TSC. This site has no tie to them and is not responsible for their content.

Common questions

What is tuberous sclerosis?

Tuberous sclerosis complex (TSC) is a genetic condition that makes noncancerous growths form in many parts of the body, including the brain, skin, heart, kidneys, lungs and eyes. It is caused by a change in the TSC1 or TSC2 gene and affects about 1 in 6,000 to 10,000 people. It varies a lot: some people have normal intelligence and no seizures, while others have intellectual disability or hard-to-control seizures.

Is tuberous sclerosis inherited?

Sometimes. About one third of people with TSC inherit the gene change from a parent who has it. The other two thirds have a new gene change and no family history. A parent with TSC has a 50% chance of passing it to each child.

What are the first signs of tuberous sclerosis in a baby?

Often a heart tumor called a cardiac rhabdomyoma, which can be seen on ultrasound before birth, or pale patches of skin (hypomelanotic macules, sometimes called ash leaf spots), which are usually present at birth or in infancy.

How common are seizures in tuberous sclerosis?

Very common. In a large international registry, 83.6% of people with TSC had epilepsy, and 38.9% had infantile spasms. In a US clinic study, 85.2% had seizures and 63.2% had their first seizure in the first year of life.

How is tuberous sclerosis treated?

There is no cure, so each problem is treated on its own. Vigabatrin is the first-line medicine for infantile spasms in TSC. Everolimus is approved for some brain tumors (SEGA) from age 1, for TSC-related focal seizures as an add-on from age 2, and for kidney angiomyolipomas in adults. Other options include epilepsy surgery, laser treatment for facial angiofibromas, and support for learning and behavior.

References

  1. 1.Tuberous sclerosis complex. MedlinePlus Genetics (National Library of Medicine). Source
  2. 2.Chu-Shore CJ, Major P, Camposano S, Muzykewicz D, Thiele EA. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia. 2010;51(7):1236-1241. PMID 20041940 · DOI 10.1111/j.1528-1167.2009.02474.x PubMedDOI
  3. 3.Tuberous sclerosis. MedlinePlus Medical Encyclopedia (National Library of Medicine). Source
  4. 4.Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2013;381(9861):125-132. PMID 23158522 · DOI 10.1016/S0140-6736(12)61134-961134-9) · NCT00789828 PubMedDOI
  5. 5.Northrup H, Krueger DA; International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013;49(4):243-254. PMID 24053982 · DOI 10.1016/j.pediatrneurol.2013.08.001 · PMC4080684 PubMedDOI
  6. 6.ICD-10-CM code Q85.1, Tuberous sclerosis. NLM Clinical Table Search Service, ICD-10-CM (National Library of Medicine). Source
  7. 7.Northrup H, Aronow ME, Bebin EM, et al. Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. Pediatr Neurol. 2021;123:50-66. PMID 34399110 · DOI 10.1016/j.pediatrneurol.2021.07.011 PubMedDOI
  8. 8.Nabbout R, Belousova E, Benedik MP, et al.; TOSCA Consortium and TOSCA Investigators. Epilepsy in tuberous sclerosis complex: Findings from the TOSCA Study. Epilepsia Open. 2019;4(1):73-84. PMID 30868117 · DOI 10.1002/epi4.12286 PubMedDOI
  9. 9.Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2013;381(9869):817-824. PMID 23312829 · DOI 10.1016/S0140-6736(12)61767-X61767-X) · NCT00790400 PubMedDOI
  10. 10.Bebin EM, Peters JM, Porter BE, et al. Early Treatment with Vigabatrin Does Not Decrease Focal Seizures or Improve Cognition in Tuberous Sclerosis Complex: The PREVeNT Trial. Ann Neurol. 2024;95(1):15-26 (Epub 2023). PMID 37638552 · DOI 10.1002/ana.26778 · NCT02849457 PubMedDOI
  11. 11.Kotulska K, Kwiatkowski DJ, Curatolo P, et al. Prevention of Epilepsy in Infants with Tuberous Sclerosis Complex in the EPISTOP Trial. Ann Neurol. 2021;89(2):304-314. PMID 33180985 · DOI 10.1002/ana.25956 · NCT02098759 PubMedDOI
  12. 12.Hancock E, Osborne JP. Vigabatrin in the treatment of infantile spasms in tuberous sclerosis: literature review. J Child Neurol. 1999;14(2):71-74. PMID 10073425 · DOI 10.1177/088307389901400201 PubMedDOI
  13. 13.Erdemir G, Rao CK, Pino AF, et al. Diagnosis and management guidelines for infantile epileptic spasms syndrome around the world: A scoping review and comparative study of international approaches. Epilepsia. 2026;67(9):4600-4617. PMID 42274306 · DOI 10.1002/epi.70329 PubMedDOI
  14. 14.VIGAFYDE (vigabatrin) oral solution prescribing information, revised 11/2025. Source
  15. 15.Yuskaitis CJ, Mytinger JR, Baumer FM, et al. Association of Time to Clinical Remission With Sustained Resolution in Children With New-Onset Infantile Spasms. Neurology. 2022;99(22):e2494-e2503. PMID 36038267 · DOI 10.1212/WNL.0000000000201232 PubMedDOI
  16. 16.Gibson R, Klima R, Van Horn J. Liquid Medication Dosing Errors: Comparison of a Ready-to-Use Vigabatrin Solution to Reconstituted Solutions of Vigabatrin Powder for Oral Solution. Adv Ther. 2025;42(3):1484-1493. PMID 39899223 · DOI 10.1007/s12325-024-03089-0 · PMC11868180 (Epub Feb 2025; often cited as 2024) PubMedDOI
  17. 17.AFINITOR (everolimus) tablets and AFINITOR DISPERZ (everolimus tablets for oral suspension) prescribing information, revised 6/2026. Source
  18. 18.French JA, Lawson JA, Yapici Z, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016;388(10056):2153-2163. PMID 27613521 · DOI 10.1016/S0140-6736(16)31419-231419-2) · NCT01713946 PubMedDOI

All sources used on this site, with summaries